| «« | Feb 2008 | »» | ||||
| S | M | T | W | T | F | S |
|
1
|
2
|
|||||
| 3 |
4
|
5
|
6 |
7
|
8
|
9 |
| 10 |
11
|
12
|
13
|
14
|
15
|
16
|
| 17 |
18
|
19
|
20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | |
KOCO-5, Oklahoma City:
Reuters:
Gender differences found in brain's serotonin system
Fox News:
Insomnia often untreated in patients with mental disorders


PITTSBURGH, Oct. 27 /PRNewswire-FirstCall/ - Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration's (FDA) Psychopharmacalogic Drugs Advisory Committee voted EMSAM(R) (selegiline transdermal system) could be safely administered without dietary modifications at 20 mg. EMSAM 30 and 40 mg will be administered with tyramine dietary modifications as originally proposed by Somerset Pharmaceuticals, Inc. It should be noted that the FDA is not bound by the Committee's recommendation.links: digg this del.icio.us technorati reddit